Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escherichia coli Symbio DSM 17252
- Development stage
- Phase 4
- Lead developer
- Symbiopharm
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Escherichia coli Symbio DSM 17252** is a nonpathogenic probiotic *Escherichia coli* preparation used as the active bacterial component of the oral medicinal product **Symbioflor 2**. The product contains a bacterial concentrate with viable *E. coli* and autolysed bacterial material and is marketed by SymbioPharm for treatment of irritable bowel syndrome in adults. Its intended activity is microbiome- and gut immune-system modulation rather than binding to a defined molecular drug target. European regulators concluded that Symbioflor 2 could remain authorised for irritable bowel syndrome but not for the broader indication of functional gastrointestinal disorders. ([symbiopharm.de](https://www.symbiopharm.de/en/products/symbioflor-2))
- Brand names
- Symbioflor 2Symbioflor2Symbioflor-2Symbioflor E. coli
- Other names
- E. coli SymbioEscherichia coli SymbioEscherichia coli Symbio DSM 17252
Beyond the preview
Go deeper on Escherichia coli Symbio DSM 17252.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Escherichia coli Symbio DSM 17252.